Kalos Therapeutics is devoted to treating the unmet medical needs of people and animals living with debilitating, orphan, or rare diseases by discovering and developing novel therapies.
Kalos is developing a groundbreaking approach to treating cancers and related comorbidities. This revolutionary technology is based upon leveraging a natural, known mechanism to regulate cell growth.
Kalos has successfully leveraged the natural antiproliferative activity of this family of peptides creating a new chemical entity in our patent pending Kalos Motif (s). This platform solidifies a never before seen anti-cancer approach which slows tumor growth and addresses severe comorbidities. Our compounds contain characteristics the body uses to also control hemodynamics and balancing that system to stay in homeostasis.
Kalos also is focused on therapeutic approaches to retinal diseases. This technology leverages our therapeutic cell signaling power, which blocks VEGF signaling in wet Age-related Macular Degeneration (AMD). An additional effect triggers immunologic processes that remove the dead cellular debris while ending the formation of frail capillaries that lead to blindness. This therapeutic application can enhance the treatment of orphan diseases in this space, such as diabetic macular edema.
Kalos successfully leverages the diuretic and therapeutic effects of ANP to replace Lasix (furosemide), banned as a race day medication in Thoroughbred racehorses and other competition horses. The equine market is over a billion dollars per annum globally, and revenue for our animal health division is anticipated within two calendar years.
Kalos peptides inhibited up to 40% of COV-2 spike peptides from its binding domain in the ACE receptor, demonstrating a peptide-peptide interaction producing inhibition. This ability to treat very ill patients hospitalized dosed intravenously is an advance for treating this disease in all patients.